 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 1694
S.P. 559 In Senate,  May 7, 2019
An Act  To Amend the Mental Health  Insurance  Coverage Laws
Reference to the Committee on Health  Coverage, Insurance and Financial Services 
suggested and ordered printed.
DAREK M.  GRANT
Secretary of the Senate
Presented by Senator GRATWICK of Penobscot.
Cosponsored by Representative SCHNECK  of Bangor and
Senators: CARPENTER of Aroostook, CLAXTON of Androscoggin, DILL of Penobscot, MILLETT of  Cumberland,  ROSEN of Hancock.

Page 1 - 129LR2169(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  24 MRSA §2325-A, sub-§8, as amended by PL 1995, c. 407, §3, is 
3repealed and the following enacted in its place:
48.  Reports to the superintendent.  A nonprofit hospital and medical service 
5organization shall submit annual reports in accordance with this subsection.
6A.  A nonprofit hospital or medical service organization subject to this section shall 
7report its experience for each calendar year to the superintendent no later than April 
830th of the following year.  The report must be in a form prescribed by the 
9superintendent and include the amount of claims paid in this State for the services 
10required by this section and the total amount of claims paid in this State for group 
11health care contracts, both separated according to those paid for inpatient, day 
12treatment and outpatient services.  The superintendent shall compile this data for all 
13nonprofit hospitals and medical service organizations in an annual report.
14B.  A nonprofit hospital or medical service organization subject to this section shall 
15submit an annual report to the superintendent no later than April 30th that contains 
16the following information:
17(1)  A description of the process used to develop or select the medically 
18necessary health care criteria for mental illness and substance use disorder 
19benefits and the process used to develop or select the medically necessary health 
20care criteria for medical and surgical benefits;
21(2)  Identification of all nonquantitative treatment limitations that are applied to 
22mental illness and substance use disorder benefits and medical and surgical 
23benefits within each classification of benefits.  The report must include 
24information demonstrating that each nonquantitative treatment limitation that 
25applies to mental illness and substance use disorder benefits also applies to 
26medical and surgical benefits within any classification of benefits; and
27(3)  The results of an analysis that demonstrate that for the medically necessary 
28health care criteria described in subparagraph (1) and for each nonquantitative 
29treatment limitation identified in subparagraph (2), as written and in operation, 
30the processes, strategies, evidentiary standards or other factors used in applying 
31the medically necessary health care criteria and each nonquantitative treatment 
32limitation to mental illness and substance use disorder benefits within each 
33classification of benefits are comparable to, and are applied no more stringently 
34than, the processes, strategies, evidentiary standards or other factors used in 
35applying the medically necessary health care criteria and each nonquantitative 
36treatment limitation to medical and surgical benefits within the corresponding 
37classification of benefits.  At a minimum, the results of the analysis must:
38(a)  Identify the factors used to determine that a nonquantitative treatment 
39limitation applies to a benefit, including factors that were considered but 
40rejected;
Page 2 - 129LR2169(01)-11(b)  Identify and define the specific evidentiary standards used to define the 
2factors and any other evidence relied upon in designing each nonquantitative 
3treatment limitation;
4(c)  Identify and describe the comparative analyses, including the results of 
5the analyses, used to determine that the processes and strategies used to 
6design each nonquantitative treatment limitation, as written, for mental 
7illness and substance use disorder benefits are comparable to, and are applied 
8no more stringently than, the processes and strategies used to design each 
9nonquantitative treatment limitation, as written, for medical and surgical 
10benefits;
11(d)  Identify and describe the comparative analyses, including the results of 
12the analyses, used to determine that the processes and strategies used to apply 
13each nonquantitative treatment limitation, in operation, for mental illness and 
14substance use disorder benefits are comparable to, and applied no more 
15stringently than, the processes and strategies used to apply each 
16nonquantitative treatment limitation, in operation, for medical and surgical 
17benefits; and
18(e)  Disclose the specific findings and conclusions reached by the nonprofit 
19hospital or medical service organization that the results of the analyses in this 
20subparagraph indicate that the nonprofit hospital or medical service 
21organization is in compliance with this section and the federal Paul Wellstone 
22and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 
23and its implementing and related regulations, which include 45 Code of 
24Federal Regulations, Sections 146.136, 147.160 and 156.115(a)(3).
25For the purposes of this paragraph, "nonquantitative treatment limitation" means a 
26limitation that is not expressed numerically but otherwise limits the scope or duration 
27of benefits for treatment.
28Sec. 2.  24 MRSA §2325-D is enacted to read:
29§2325-D.  Prescription drug benefits for substance use disorder treatment
30A nonprofit hospital or medical service organization that issues group health care 
31contracts that provide prescription drug benefits for the treatment of substance use 
32disorder:
331.  Prior authorization requirements.  May not impose any prior authorization 
34requirements on any prescription medication approved by the federal Food and Drug 
35Administration for the treatment of substance use disorder;
362.  Step therapy requirements.  May not impose any step therapy requirements 
37before the nonprofit hospital or medical service organization authorizes coverage for a 
38prescription medication approved by the federal Food and Drug Administration for the 
39treatment of substance use disorder;
403.  Drug formulary.  Shall place all prescription medications approved by the federal 
41Food and Drug Administration for the treatment of substance use disorder on the lowest 
Page 3 - 129LR2169(01)-11tier of the drug formulary developed and maintained by the nonprofit hospital or medical 
2service organization; and
34.  Court-ordered medication.  May not exclude coverage for any prescription 
4medication approved by the federal Food and Drug Administration for the treatment of 
5substance use disorder or any associated counseling or wraparound services on the 
6grounds that such medications and services were court ordered.
7Sec. 3.  24-A MRSA §238 is enacted to read:
8§238.  Implementation of federal mental health parity laws
91.  Implementation of federal mental health parity laws.  The superintendent shall 
10implement and enforce applicable provisions of the federal Paul Wellstone and Pete 
11Domenici Mental Health Parity and Addiction Equity Act of 2008, and any amendments 
12to and federal guidance or regulations relevant to that Act, including 45 Code of Federal 
13Regulations, Sections 146.136, 147.136, 147.160 and 156.115(a)(3), by:
14A.  Proactively ensuring compliance by insurers, health maintenance organizations 
15and nonprofit hospital or medical service organizations that execute, deliver, issue for 
16delivery, continue or renew individual policies or individual and group health care 
17contracts;
18B.  Evaluating all consumer or provider complaints regarding mental illness and 
19substance use disorder coverage for possible parity violations;
20C.  Performing parity compliance market conduct examinations of insurers, health 
21maintenance organizations and nonprofit hospital or medical service organizations 
22that execute, deliver, issue for delivery, continue or renew individual policies or 
23individual and group health care contracts, particularly market conduct examinations 
24that focus on nonquantitative treatment limitations, including, but not limited to, prior 
25authorization, concurrent review, retrospective review, step therapy, network 
26admission standards, reimbursement rates and geographic restrictions; and
27D.  Requesting that insurers, health maintenance organizations and nonprofit hospital 
28or medical service organizations submit comparative analyses during the form review 
29process demonstrating how they design and apply nonquantitative treatment 
30limitation, both as written and in operation, for mental illness and substance use 
31disorder benefits as compared to how they design and apply nonquantitative 
32treatment limitation, as written and in operation, for medical and surgical benefits.
33The superintendent may adopt rules, as authorized under section 212, as may be 
34necessary to effectuate any provisions of the federal Paul Wellstone and Pete Domenici 
35Mental Health Parity and Addiction Equity Act of 2008 that relate to the business of 
36insurance.  Rules adopted pursuant to this subsection are routine technical rules as 
37defined in Title 5, chapter 375, subchapter 2-A.
382.  Report.  No later than March 1, 2020 and periodically thereafter, the 
39superintendent shall provide a report and educational presentation to the Legislature.  The 
40report must:
Page 4 - 129LR2169(01)-11A.  Cover the methodology the superintendent is using to check for compliance with 
2the federal Paul Wellstone and Pete Domenici Mental Health Parity and Addiction 
3Equity Act of 2008 and any federal regulations or guidance relating to the compliance 
4and oversight of that Act;
5B.  Cover the methodology the superintendent is using to check for compliance with 
6sections 2749-C, 2842, 2843 and 4234-A and Title 24, sections 2325-A and 2329;
7C.  Identify market conduct examinations conducted or completed during the 
8preceding 12-month period regarding compliance with parity in mental illness and 
9substance use disorder benefits under state and federal laws, and summarize the 
10results of such market conduct examinations;
11D.  Detail any educational or corrective actions the superintendent has taken to ensure 
12insurer compliance with the federal Paul Wellstone and Pete Domenici Mental Health 
13Parity and Addiction Equity Act of 2008 and sections 2749-C, 2842, 2843 and 
144234-A and Title 24, sections 2325-A and 2329; and
15E.  Be written in nontechnical, understandable language and made available to the 
16public by posting the report on the bureau's publicly accessible website and other 
17means the superintendent finds appropriate.
18Sec. 4.  24-A MRSA §2749-C, sub-§4, as enacted by PL 1995, c. 407, §5, is 
19repealed and the following enacted in its place:
204.  Reports to the superintendent.  An insurer shall submit annual reports in 
21accordance with this subsection.
22A.  An insurer subject to this section shall report its experience for each calendar year 
23to the superintendent no later than April 30th of the following year.  The report must 
24be in a form prescribed by the superintendent and include the amount of claims paid 
25in this State for the services required by this section and the total amount of claims 
26paid in this State for individual health care policies, both separated according to those 
27paid for inpatient, day treatment and outpatient services, as those terms are defined in 
28section 2843.  The superintendent shall compile this data for all insurers in an annual 
29report.
30B.  An insurer subject to this section shall submit an annual report to the 
31superintendent no later than April 30th that contains the following information:
32(1)  A description of the process used to develop or select the medically 
33necessary health care criteria for mental illness and substance use disorder 
34benefits and the process used to develop or select the medically necessary health 
35care criteria for medical and surgical benefits;
36(2)  Identification of all nonquantitative treatment limitations that are applied to 
37mental illness and substance use disorder benefits and medical and surgical 
38benefits within each classification of benefits.  The report must include 
39information demonstrating that each nonquantitative treatment limitation that 
40applies to mental illness and substance use disorder benefits also applies to 
41medical and surgical benefits within any classification of benefits; and
Page 5 - 129LR2169(01)-11(3)  The results of an analysis that demonstrate that for the medically necessary 
2health care criteria described in subparagraph (1) and for each nonquantitative 
3treatment limitation identified in subparagraph (2), as written and in operation, 
4the processes, strategies, evidentiary standards or other factors used in applying 
5the medically necessary health care criteria and each nonquantitative treatment 
6limitation to mental illness and substance use disorder benefits within each 
7classification of benefits are comparable to, and are applied no more stringently 
8than, the processes, strategies, evidentiary standards or other factors used in 
9applying the medically necessary health care criteria and each nonquantitative 
10treatment limitation to medical and surgical benefits within the corresponding 
11classification of benefits.  At a minimum, the results of the analysis must:
12(a)  Identify the factors used to determine that a nonquantitative treatment 
13limitation applies to a benefit, including factors that were considered but 
14rejected;
15(b)  Identify and define the specific evidentiary standards used to define the 
16factors and any other evidence relied upon in designing each nonquantitative 
17treatment limitation;
18(c)  Identify and describe the comparative analyses, including the results of 
19the analyses, used to determine that the processes and strategies used to 
20design each nonquantitative treatment limitation, as written, for mental 
21illness and substance use disorder benefits are comparable to, and are applied 
22no more stringently than, the processes and strategies used to design each 
23nonquantitative treatment limitation, as written, for medical and surgical 
24benefits;
25(d)  Identify and describe the comparative analyses, including the results of 
26the analyses, used to determine that the processes and strategies used to apply 
27each nonquantitative treatment limitation, in operation, for mental illness and 
28substance use disorder benefits are comparable to, and applied no more 
29stringently than, the processes and strategies used to apply each 
30nonquantitative treatment limitation, in operation, for medical and surgical 
31benefits; and
32(e)  Disclose the specific findings and conclusions reached by the insurer that 
33the results of the analyses in this subparagraph indicate that the insurer is in 
34compliance with this section and the federal Paul Wellstone and Pete 
35Domenici Mental Health Parity and Addiction Equity Act of 2008 and its 
36implementing and related regulations, which include 45 Code of Federal 
37Regulations, Sections 146.136, 147.160 and 156.115(a)(3).
38For the purposes of this paragraph, "nonquantitative treatment limitation" means a 
39limitation that is not expressed numerically but otherwise limits the scope or duration 
40of benefits for treatment.
41Sec. 5.  24-A MRSA §2749-D is enacted to read:
Page 6 - 129LR2169(01)-11§2749-D.  Prescription drug benefits for substance use disorder treatment
2An insurer that executes, delivers, issues for delivery, continues or renews individual 
3health care policies that provide prescription drug benefits for the treatment of substance 
4use disorder:
51.  Prior authorization requirements.  May not impose any prior authorization 
6requirements on any prescription medication approved by the federal Food and Drug 
7Administration for the treatment of substance use disorder;
82.  Step therapy requirements.  May not impose any step therapy requirements 
9before the insurer authorizes coverage for a prescription medication approved by the 
10federal Food and Drug Administration for the treatment of substance use disorder;
113.  Drug formulary.  Shall place all prescription medications approved by the federal 
12Food and Drug Administration for the treatment of substance use disorder on the lowest 
13tier of the drug formulary developed and maintained by the insurer; and
144.  Court-ordered medication.  May not exclude coverage for any prescription 
15medication approved by the federal Food and Drug Administration for the treatment of 
16substance use disorder or any associated counseling or wraparound services on the 
17grounds that such medications and services were court ordered.
18Sec. 6.  24-A MRSA §2843, sub-§7, as amended by PL 1995, c. 407, §8, is 
19repealed and the following enacted in its place:
207.  Reports to the superintendent.  An insurer shall submit annual reports in 
21accordance with this subsection.
22A.  An insurer subject to this section shall report its experience for each calendar year 
23to the superintendent no later than April 30th of the following year.  The report must 
24be in a form prescribed by the superintendent and include the amount of claims paid 
25in this State for the services required by this section and the total amount of claims 
26paid in this State for group health care contracts, both separated according to those 
27paid for inpatient, day treatment and outpatient services.  The superintendent shall 
28compile this data for all insurers in an annual report.
29B.  An insurer subject to this section shall submit an annual report to the 
30superintendent no later than April 30th that contains the following information:
31(1)  A description of the process used to develop or select the medically 
32necessary health care criteria for mental illness and substance use disorder 
33benefits and the process used to develop or select the medically necessary health 
34care criteria for medical and surgical benefits;
35(2)  Identification of all nonquantitative treatment limitations that are applied to 
36mental illness and substance use disorder benefits and medical and surgical 
37benefits within each classification of benefits.  The report must include 
38information demonstrating that each nonquantitative treatment limitation that 
39applies to mental illness and substance use disorder benefits also applies to 
40medical and surgical benefits within any classification of benefits; and
Page 7 - 129LR2169(01)-11(3)  The results of an analysis that demonstrate that for the medically necessary 
2health care criteria described in subparagraph (1) and for each nonquantitative 
3treatment limitation identified in subparagraph (2), as written and in operation, 
4the processes, strategies, evidentiary standards or other factors used in applying 
5the medically necessary health care criteria and each nonquantitative treatment 
6limitation to mental illness and substance use disorder benefits within each 
7classification of benefits are comparable to, and are applied no more stringently 
8than, the processes, strategies, evidentiary standards or other factors used in 
9applying the medically necessary health care criteria and each nonquantitative 
10treatment limitation to medical and surgical benefits within the corresponding 
11classification of benefits.  At a minimum, the results of the analysis must:
12(a)  Identify the factors used to determine that a nonquantitative treatment 
13limitation applies to a benefit, including factors that were considered but 
14rejected;
15(b)  Identify and define the specific evidentiary standards used to define the 
16factors and any other evidence relied upon in designing each nonquantitative 
17treatment limitation;
18(c)  Identify and describe the comparative analyses, including the results of 
19the analyses, used to determine that the processes and strategies used to 
20design each nonquantitative treatment limitation, as written, for mental 
21illness and substance use disorder benefits are comparable to, and are applied 
22no more stringently than, the processes and strategies used to design each 
23nonquantitative treatment limitation, as written, for medical and surgical 
24benefits;
25(d)  Identify and describe the comparative analyses, including the results of 
26the analyses, used to determine that the processes and strategies used to apply 
27each nonquantitative treatment limitation, in operation, for mental illness and 
28substance use disorder benefits are comparable to, and applied no more 
29stringently than, the processes and strategies used to apply each 
30nonquantitative treatment limitation, in operation, for medical and surgical 
31benefits; and
32(e)  Disclose the specific findings and conclusions reached by the insurer that 
33the results of the analyses in this subparagraph indicate that the insurer is in 
34compliance with this section and the federal Paul Wellstone and Pete 
35Domenici Mental Health Parity and Addiction Equity Act of 2008 and its 
36implementing and related regulations, which include 45 Code of Federal 
37Regulations, Sections 146.136, 147.160 and 156.115(a)(3).
38For the purposes of this paragraph, "nonquantitative treatment limitation" means a 
39limitation that is not expressed numerically but otherwise limits the scope or duration 
40of benefits for treatment.
41Sec. 7.  24-A MRSA §2847-V is enacted to read:
Page 8 - 129LR2169(01)-11§2847-V.  Prescription drug benefits for substance use disorder treatment
2An insurer that issues group health care contracts that provide prescription drug 
3benefits for the treatment of substance use disorder:
41.  Prior authorization requirements.  May not impose any prior authorization 
5requirements on any prescription medication approved by the federal Food and Drug 
6Administration for the treatment of substance use disorder;
72.  Step therapy requirements.  May not impose any step therapy requirements 
8before the insurer authorizes coverage for a prescription medication approved by the 
9federal Food and Drug Administration for the treatment of substance use disorder;
103.  Drug formulary.  Shall place all prescription medications approved by the federal 
11Food and Drug Administration for the treatment of substance use disorder on the lowest 
12tier of the drug formulary developed and maintained by the insurer; and
134.  Court-ordered medication.  May not exclude coverage for any prescription 
14medication approved by the federal Food and Drug Administration for the treatment of 
15substance use disorder or any associated counseling or wraparound services on the 
16grounds that such medications and services were court ordered.
17Sec. 8.  24-A MRSA §4234-A, sub-§10, as enacted by PL 1995, c. 407, §10, is 
18repealed and the following enacted in its place:
1910.  Reports to the superintendent.  A health maintenance organization shall submit 
20annual reports in accordance with this subsection.
21A.  A health maintenance organization subject to this section shall report its 
22experience for each calendar year to the superintendent no later than April 30th of the 
23following year.  The report must be in a form prescribed by the superintendent and 
24include the amount of claims paid in this State for the services required by this 
25section and the total amount of claims paid in this State for individual and group 
26health care contracts, both separated according to those paid for inpatient, day 
27treatment and outpatient services.  The superintendent shall compile this data for all 
28health maintenance organizations in an annual report.
29B.  A health maintenance organization subject to this section shall submit an annual 
30report to the superintendent no later than April 30th that contains the following 
31information:
32(1)  A description of the process used to develop or select the medically 
33necessary health care criteria for mental illness and substance use disorder 
34benefits and the process used to develop or select the medically necessary health 
35care criteria for medical and surgical benefits;
36(2)  Identification of all nonquantitative treatment limitations that are applied to 
37mental illness and substance use disorder benefits and medical and surgical 
38benefits within each classification of benefits.  The report must include 
39information demonstrating that each nonquantitative treatment limitation that 
Page 9 - 129LR2169(01)-11applies to mental illness and substance use disorder benefits also applies to 
2medical and surgical benefits within any classification of benefits; and
3(3)  The results of an analysis that demonstrate that for the medically necessary 
4health care criteria described in subparagraph (1) and for each nonquantitative 
5treatment limitation identified in subparagraph (2), as written and in operation, 
6the processes, strategies, evidentiary standards or other factors used in applying 
7the medically necessary health care criteria and each nonquantitative treatment 
8limitation to mental illness and substance use disorder benefits within each 
9classification of benefits are comparable to, and are applied no more stringently 
10than, the processes, strategies, evidentiary standards or other factors used in 
11applying the medically necessary health care criteria and each nonquantitative 
12treatment limitation to medical and surgical benefits within the corresponding 
13classification of benefits.  At a minimum, the results of the analysis must:
14(a)  Identify the factors used to determine that a nonquantitative treatment 
15limitation applies to a benefit, including factors that were considered but 
16rejected;
17(b)  Identify and define the specific evidentiary standards used to define the 
18factors and any other evidence relied upon in designing each nonquantitative 
19treatment limitation;
20(c)  Identify and describe the comparative analyses, including the results of 
21the analyses, used to determine that the processes and strategies used to 
22design each nonquantitative treatment limitation, as written, for mental 
23illness and substance use disorder benefits are comparable to, and are applied 
24no more stringently than, the processes and strategies used to design each 
25nonquantitative treatment limitation, as written, for medical and surgical 
26benefits;
27(d)  Identify and describe the comparative analyses, including the results of 
28the analyses, used to determine that the processes and strategies used to apply 
29each nonquantitative treatment limitation, in operation, for mental illness and 
30substance use disorder benefits are comparable to, and applied no more 
31stringently than, the processes and strategies used to apply each 
32nonquantitative treatment limitation, in operation, for medical and surgical 
33benefits; and
34(e)  Disclose the specific findings and conclusions reached by the health 
35maintenance organization that the results of the analyses in this subparagraph 
36indicate that the health maintenance organization is in compliance with this 
37section and the federal Paul Wellstone and Pete Domenici Mental Health 
38Parity and Addiction Equity Act of 2008 and its implementing and related 
39regulations, which include 45 Code of Federal Regulations, Sections 
40146.136, 147.160 and 156.115(a)(3).
41For the purposes of this paragraph, "nonquantitative treatment limitation" means a 
42limitation that is not expressed numerically but otherwise limits the scope or duration 
43of benefits for treatment.
Page 10 - 129LR2169(01)-11Sec. 9.  24-A MRSA §4234-F is enacted to read:
2§4234-F.  Prescription drug benefits for substance use disorder treatment
3A health maintenance organization that executes, delivers, issues for delivery, 
4continues or renews individual and group health care contracts that provide prescription 
5drug benefits for the treatment of substance use disorder:
61.  Prior authorization requirements.  May not impose any prior authorization 
7requirements on any prescription medication approved by the federal Food and Drug 
8Administration for the treatment of substance use disorder;
92.  Step therapy requirements.  May not impose any step therapy requirements 
10before the health maintenance organization authorizes coverage for a prescription 
11medication approved by the federal Food and Drug Administration for the treatment of 
12substance use disorder;
133.  Drug formulary.  Shall place all prescription medications approved by the federal 
14Food and Drug Administration for the treatment of substance use disorder on the lowest 
15tier of the drug formulary developed and maintained by the health maintenance 
16organization; and
174.  Court-ordered medication.  May not exclude coverage for any prescription 
18medication approved by the federal Food and Drug Administration for the treatment of 
19substance use disorder or any associated counseling or wraparound services on the 
20grounds that such medications and services were court ordered.
21Sec. 10.  Application.  The requirements of this Act apply to all insurers, health 
22maintenance organizations and nonprofit hospital or medical service organizations that 
23execute, deliver, issue for delivery, continue or renew individual and group health care 
24policies, contracts and certificates in this State on or after January 1, 2020.
25SUMMARY
26This bill requires insurers, health maintenance organizations and nonprofit hospital or 
27medical service organizations to submit mental health and substance use disorder parity 
28compliance reports to the Superintendent of Insurance.  It specifies how the 
29superintendent of Insurance may enforce parity requirements and provides parity 
30reporting requirements for the superintendent.  The bill also prohibits certain types of 
31medical management protocols from being used in conjunction with prescription 
32medications used to treat substance use disorder.
